Mfolfirinox And STEreotactic Radiotherapy for Patients with Locally Advanced paNcreatic cancer (MASTERPLAN Pilot): a feasibility study to assess if mFOLFIRINOX chemotherapy and Stereotactic Body Radiation Therapy (SBRT) is a feasible neoadjuvant treatment option with acceptable acute toxicity rates for patients with Borderline Resectable Pancreatic Adenocarcinoma (BRPC) or Unresectable Pancreatic Adenocarcinoma (UPC)

iverpool Hospital0 个研究点目标入组 11 人开始时间: 2017年12月19日最近更新: 2022年6月20日

适应症

试验速览

暂无简介。

•Age greater than or equal to 18 years and able to give informed consent.
•Patients with histologically confirmed adenocarcinoma of the pancreas that is classified as BRPC or UPC, as per NCCN guidelines.
•ECOG performance status 0 or 1.
•Adequate bone marrow function (absolute neutrophil count ((ANC) greater than 1.5, platelets greater than 100).
•Adequate liver function (albumin greater than 25 g/L, bilirubin less than or equal to 26 micromol/L; transaminases (ALT/AST) less than or equal to 5 times the upper limit of normal (ULN)).
•Adequate renal function (creatinine less than or equal to 1.5 times the ULN).

•Age 70 years and over.
•Patients with resectable or metastatic pancreatic cancer.
•Neuroendocrine pancreatic carcinoma.
•Previous chemotherapy or abdominal radiotherapy.
•Previous diagnosis of cancer within the last 5 years (excluding non-melanoma skin cancers, and carcinoma in situ).
•Chronic diarrhoea or peripheral neuropathy equal to or greater than grade 2.
•Non-controlled coronary artery disease or myocardial infarction within the last 6 months.
•Known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, capecitabine.
•Patient will be ineligible for fMRI if they have contraindication to MRI. They will still have other imaging performed (18FDG-PET and 18F-MISO).
•Patients with portal hypertension, coagulopathy or an inaccessible portal vein will not have portal vein blood sampling done as part of CTC/cPSC sub-study.

发起方

iverpool Hospital